nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0811	0.463	CbGbCtD
Pimecrolimus—CYP3A4—Progesterone—uterine cancer	0.0537	0.306	CbGbCtD
Pimecrolimus—CYP3A4—Etoposide—uterine cancer	0.024	0.137	CbGbCtD
Pimecrolimus—CYP3A4—Doxorubicin—uterine cancer	0.0164	0.0935	CbGbCtD
Pimecrolimus—MTOR—myometrium—uterine cancer	0.0101	0.0641	CbGeAlD
Pimecrolimus—FKBP1A—myometrium—uterine cancer	0.00909	0.0577	CbGeAlD
Pimecrolimus—MTOR—epithelium—uterine cancer	0.00794	0.0503	CbGeAlD
Pimecrolimus—MTOR—smooth muscle tissue—uterine cancer	0.00765	0.0485	CbGeAlD
Pimecrolimus—MTOR—renal system—uterine cancer	0.00736	0.0467	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—uterine cancer	0.00714	0.0453	CbGeAlD
Pimecrolimus—MTOR—endometrium—uterine cancer	0.00712	0.0452	CbGeAlD
Pimecrolimus—FKBP1A—uterine cervix—uterine cancer	0.00708	0.0449	CbGeAlD
Pimecrolimus—MTOR—mammalian vulva—uterine cancer	0.00688	0.0437	CbGeAlD
Pimecrolimus—FKBP1A—smooth muscle tissue—uterine cancer	0.00688	0.0436	CbGeAlD
Pimecrolimus—FKBP1A—decidua—uterine cancer	0.00674	0.0428	CbGeAlD
Pimecrolimus—FKBP1A—renal system—uterine cancer	0.00662	0.042	CbGeAlD
Pimecrolimus—MTOR—uterus—uterine cancer	0.00656	0.0416	CbGeAlD
Pimecrolimus—FKBP1A—endometrium—uterine cancer	0.0064	0.0406	CbGeAlD
Pimecrolimus—FKBP1A—mammalian vulva—uterine cancer	0.00619	0.0393	CbGeAlD
Pimecrolimus—FKBP1A—uterus—uterine cancer	0.0059	0.0374	CbGeAlD
Pimecrolimus—MTOR—female reproductive system—uterine cancer	0.0059	0.0374	CbGeAlD
Pimecrolimus—MTOR—female gonad—uterine cancer	0.00536	0.034	CbGeAlD
Pimecrolimus—MTOR—vagina—uterine cancer	0.00533	0.0338	CbGeAlD
Pimecrolimus—FKBP1A—female reproductive system—uterine cancer	0.0053	0.0336	CbGeAlD
Pimecrolimus—FKBP1A—female gonad—uterine cancer	0.00482	0.0306	CbGeAlD
Pimecrolimus—FKBP1A—vagina—uterine cancer	0.0048	0.0304	CbGeAlD
Pimecrolimus—MTOR—lymph node—uterine cancer	0.00345	0.0219	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—uterine cancer	0.0031	0.0197	CbGeAlD
Pimecrolimus—CYP3A4—renal system—uterine cancer	0.00216	0.0137	CbGeAlD
Pimecrolimus—Pneumonia—Progesterone—uterine cancer	0.0018	0.00503	CcSEcCtD
Pimecrolimus—Infestation NOS—Progesterone—uterine cancer	0.00179	0.005	CcSEcCtD
Pimecrolimus—Infestation—Progesterone—uterine cancer	0.00179	0.005	CcSEcCtD
Pimecrolimus—Bronchitis—Medroxyprogesterone Acetate—uterine cancer	0.00175	0.00489	CcSEcCtD
Pimecrolimus—Conjunctivitis—Progesterone—uterine cancer	0.00174	0.00486	CcSEcCtD
Pimecrolimus—Furuncle—Doxorubicin—uterine cancer	0.00173	0.00484	CcSEcCtD
Pimecrolimus—CYP3A4—female reproductive system—uterine cancer	0.00173	0.011	CbGeAlD
Pimecrolimus—Body temperature increased—Carboplatin—uterine cancer	0.00172	0.0048	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00169	0.00473	CcSEcCtD
Pimecrolimus—Sinusitis—Progesterone—uterine cancer	0.00168	0.00469	CcSEcCtD
Pimecrolimus—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00453	CcSEcCtD
Pimecrolimus—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00453	CcSEcCtD
Pimecrolimus—Rhinitis—Progesterone—uterine cancer	0.00161	0.0045	CcSEcCtD
Pimecrolimus—Pharyngitis—Progesterone—uterine cancer	0.0016	0.00446	CcSEcCtD
Pimecrolimus—Skin exfoliation—Etoposide—uterine cancer	0.00157	0.00437	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Epirubicin—uterine cancer	0.00155	0.00431	CcSEcCtD
Pimecrolimus—Epistaxis—Medroxyprogesterone Acetate—uterine cancer	0.00153	0.00428	CcSEcCtD
Pimecrolimus—Sinusitis—Medroxyprogesterone Acetate—uterine cancer	0.00152	0.00425	CcSEcCtD
Pimecrolimus—Eye disorder—Progesterone—uterine cancer	0.0015	0.0042	CcSEcCtD
Pimecrolimus—Folliculitis—Epirubicin—uterine cancer	0.00146	0.00408	CcSEcCtD
Pimecrolimus—Immune system disorder—Progesterone—uterine cancer	0.00145	0.00406	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Progesterone—uterine cancer	0.00145	0.00405	CcSEcCtD
Pimecrolimus—Pharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.00145	0.00404	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Doxorubicin—uterine cancer	0.00143	0.00399	CcSEcCtD
Pimecrolimus—Erythema—Progesterone—uterine cancer	0.0014	0.00391	CcSEcCtD
Pimecrolimus—Malnutrition—Progesterone—uterine cancer	0.0014	0.00391	CcSEcCtD
Pimecrolimus—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.00136	0.0038	CcSEcCtD
Pimecrolimus—Back pain—Progesterone—uterine cancer	0.00136	0.00378	CcSEcCtD
Pimecrolimus—Folliculitis—Doxorubicin—uterine cancer	0.00135	0.00378	CcSEcCtD
Pimecrolimus—Swelling—Etoposide—uterine cancer	0.00135	0.00376	CcSEcCtD
Pimecrolimus—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00368	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00131	0.00367	CcSEcCtD
Pimecrolimus—Angioedema—Progesterone—uterine cancer	0.00128	0.00357	CcSEcCtD
Pimecrolimus—Pneumonia—Dactinomycin—uterine cancer	0.00128	0.00356	CcSEcCtD
Pimecrolimus—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00127	0.00354	CcSEcCtD
Pimecrolimus—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.00127	0.00354	CcSEcCtD
Pimecrolimus—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00123	0.00343	CcSEcCtD
Pimecrolimus—Cough—Progesterone—uterine cancer	0.00122	0.00341	CcSEcCtD
Pimecrolimus—Arthralgia—Progesterone—uterine cancer	0.00119	0.00333	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00119	0.00331	CcSEcCtD
Pimecrolimus—Otitis media—Epirubicin—uterine cancer	0.00118	0.00329	CcSEcCtD
Pimecrolimus—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00324	CcSEcCtD
Pimecrolimus—Oedema—Progesterone—uterine cancer	0.00114	0.00319	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Progesterone—uterine cancer	0.00114	0.00319	CcSEcCtD
Pimecrolimus—Infection—Progesterone—uterine cancer	0.00114	0.00317	CcSEcCtD
Pimecrolimus—Pharyngitis—Dactinomycin—uterine cancer	0.00113	0.00315	CcSEcCtD
Pimecrolimus—Nervous system disorder—Progesterone—uterine cancer	0.00112	0.00313	CcSEcCtD
Pimecrolimus—Skin disorder—Progesterone—uterine cancer	0.00111	0.0031	CcSEcCtD
Pimecrolimus—Otitis media—Doxorubicin—uterine cancer	0.00109	0.00305	CcSEcCtD
Pimecrolimus—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00108	0.00302	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Epirubicin—uterine cancer	0.00108	0.003	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.003	CcSEcCtD
Pimecrolimus—Flushing—Dactinomycin—uterine cancer	0.00106	0.00295	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Progesterone—uterine cancer	0.00104	0.00291	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00289	CcSEcCtD
Pimecrolimus—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00289	CcSEcCtD
Pimecrolimus—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00103	0.00287	CcSEcCtD
Pimecrolimus—Paraesthesia—Progesterone—uterine cancer	0.00103	0.00287	CcSEcCtD
Pimecrolimus—Dyspnoea—Progesterone—uterine cancer	0.00102	0.00284	CcSEcCtD
Pimecrolimus—Bone disorder—Epirubicin—uterine cancer	0.00102	0.00284	CcSEcCtD
Pimecrolimus—Skin discolouration—Epirubicin—uterine cancer	0.00102	0.00284	CcSEcCtD
Pimecrolimus—Viral infection—Epirubicin—uterine cancer	0.00102	0.00284	CcSEcCtD
Pimecrolimus—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00102	0.00284	CcSEcCtD
Pimecrolimus—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.00281	CcSEcCtD
Pimecrolimus—Herpes simplex—Epirubicin—uterine cancer	0.000998	0.00278	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Doxorubicin—uterine cancer	0.000996	0.00278	CcSEcCtD
Pimecrolimus—Erythema—Dactinomycin—uterine cancer	0.000991	0.00276	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Progesterone—uterine cancer	0.000988	0.00275	CcSEcCtD
Pimecrolimus—Constipation—Progesterone—uterine cancer	0.000978	0.00273	CcSEcCtD
Pimecrolimus—Pain—Progesterone—uterine cancer	0.000978	0.00273	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000944	0.00263	CcSEcCtD
Pimecrolimus—Skin discolouration—Doxorubicin—uterine cancer	0.000942	0.00263	CcSEcCtD
Pimecrolimus—Bone disorder—Doxorubicin—uterine cancer	0.000942	0.00263	CcSEcCtD
Pimecrolimus—Viral infection—Doxorubicin—uterine cancer	0.000942	0.00263	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Progesterone—uterine cancer	0.000935	0.00261	CcSEcCtD
Pimecrolimus—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000931	0.0026	CcSEcCtD
Pimecrolimus—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000924	0.00258	CcSEcCtD
Pimecrolimus—Herpes simplex—Doxorubicin—uterine cancer	0.000923	0.00258	CcSEcCtD
Pimecrolimus—Pneumonia—Etoposide—uterine cancer	0.000923	0.00257	CcSEcCtD
Pimecrolimus—Infestation—Etoposide—uterine cancer	0.000917	0.00256	CcSEcCtD
Pimecrolimus—Infestation NOS—Etoposide—uterine cancer	0.000917	0.00256	CcSEcCtD
Pimecrolimus—Urticaria—Progesterone—uterine cancer	0.000909	0.00254	CcSEcCtD
Pimecrolimus—Abdominal pain—Progesterone—uterine cancer	0.000904	0.00252	CcSEcCtD
Pimecrolimus—Body temperature increased—Progesterone—uterine cancer	0.000904	0.00252	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000895	0.0025	CcSEcCtD
Pimecrolimus—Influenza like illness—Epirubicin—uterine cancer	0.000893	0.00249	CcSEcCtD
Pimecrolimus—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000886	0.00247	CcSEcCtD
Pimecrolimus—Skin exfoliation—Epirubicin—uterine cancer	0.000878	0.00245	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000848	0.00236	CcSEcCtD
Pimecrolimus—Hypersensitivity—Progesterone—uterine cancer	0.000843	0.00235	CcSEcCtD
Pimecrolimus—Influenza like illness—Doxorubicin—uterine cancer	0.000826	0.0023	CcSEcCtD
Pimecrolimus—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000823	0.0023	CcSEcCtD
Pimecrolimus—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000819	0.00229	CcSEcCtD
Pimecrolimus—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000819	0.00229	CcSEcCtD
Pimecrolimus—Skin exfoliation—Doxorubicin—uterine cancer	0.000812	0.00227	CcSEcCtD
Pimecrolimus—Pruritus—Progesterone—uterine cancer	0.000809	0.00226	CcSEcCtD
Pimecrolimus—Oedema—Dactinomycin—uterine cancer	0.000808	0.00226	CcSEcCtD
Pimecrolimus—Infection—Dactinomycin—uterine cancer	0.000803	0.00224	CcSEcCtD
Pimecrolimus—Diarrhoea—Progesterone—uterine cancer	0.000783	0.00218	CcSEcCtD
Pimecrolimus—Eye disorder—Etoposide—uterine cancer	0.00077	0.00215	CcSEcCtD
Pimecrolimus—Flushing—Etoposide—uterine cancer	0.000764	0.00213	CcSEcCtD
Pimecrolimus—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000764	0.00213	CcSEcCtD
Pimecrolimus—Immune system disorder—Etoposide—uterine cancer	0.000744	0.00208	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Etoposide—uterine cancer	0.000742	0.00207	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000737	0.00205	CcSEcCtD
Pimecrolimus—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000733	0.00205	CcSEcCtD
Pimecrolimus—Vomiting—Progesterone—uterine cancer	0.000727	0.00203	CcSEcCtD
Pimecrolimus—Rash—Progesterone—uterine cancer	0.000721	0.00201	CcSEcCtD
Pimecrolimus—Dermatitis—Progesterone—uterine cancer	0.000721	0.00201	CcSEcCtD
Pimecrolimus—Headache—Progesterone—uterine cancer	0.000717	0.002	CcSEcCtD
Pimecrolimus—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000709	0.00198	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000707	0.00197	CcSEcCtD
Pimecrolimus—Back pain—Etoposide—uterine cancer	0.000694	0.00193	CcSEcCtD
Pimecrolimus—Pain—Dactinomycin—uterine cancer	0.000691	0.00193	CcSEcCtD
Pimecrolimus—Nausea—Progesterone—uterine cancer	0.000679	0.0019	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000661	0.00184	CcSEcCtD
Pimecrolimus—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000659	0.00184	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000654	0.00183	CcSEcCtD
Pimecrolimus—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000654	0.00182	CcSEcCtD
Pimecrolimus—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000653	0.00182	CcSEcCtD
Pimecrolimus—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000649	0.00181	CcSEcCtD
Pimecrolimus—Face oedema—Epirubicin—uterine cancer	0.000644	0.0018	CcSEcCtD
Pimecrolimus—Body temperature increased—Dactinomycin—uterine cancer	0.000639	0.00178	CcSEcCtD
Pimecrolimus—Abdominal pain—Dactinomycin—uterine cancer	0.000639	0.00178	CcSEcCtD
Pimecrolimus—Cough—Etoposide—uterine cancer	0.000626	0.00175	CcSEcCtD
Pimecrolimus—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000616	0.00172	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—uterine cancer	0.00061	0.0017	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000606	0.00169	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—uterine cancer	0.000603	0.00168	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—uterine cancer	0.000597	0.00166	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—uterine cancer	0.000596	0.00166	CcSEcCtD
Pimecrolimus—Hypersensitivity—Dactinomycin—uterine cancer	0.000596	0.00166	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Etoposide—uterine cancer	0.000585	0.00163	CcSEcCtD
Pimecrolimus—Infection—Etoposide—uterine cancer	0.000581	0.00162	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—uterine cancer	0.000577	0.00161	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—uterine cancer	0.000577	0.00161	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—uterine cancer	0.000568	0.00159	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—uterine cancer	0.000564	0.00157	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—uterine cancer	0.000558	0.00156	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—uterine cancer	0.000555	0.00155	CcSEcCtD
Pimecrolimus—Diarrhoea—Dactinomycin—uterine cancer	0.000553	0.00154	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—uterine cancer	0.000552	0.00154	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000536	0.0015	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—uterine cancer	0.000534	0.00149	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—uterine cancer	0.000534	0.00149	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—uterine cancer	0.000526	0.00147	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—uterine cancer	0.000525	0.00147	CcSEcCtD
Pimecrolimus—Dyspnoea—Etoposide—uterine cancer	0.000522	0.00146	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—uterine cancer	0.000517	0.00144	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—uterine cancer	0.000514	0.00143	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—uterine cancer	0.000514	0.00143	CcSEcCtD
Pimecrolimus—Vomiting—Dactinomycin—uterine cancer	0.000514	0.00143	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—uterine cancer	0.000513	0.00143	CcSEcCtD
Pimecrolimus—Rash—Dactinomycin—uterine cancer	0.00051	0.00142	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Etoposide—uterine cancer	0.000505	0.00141	CcSEcCtD
Pimecrolimus—Pain—Etoposide—uterine cancer	0.0005	0.0014	CcSEcCtD
Pimecrolimus—Constipation—Etoposide—uterine cancer	0.0005	0.0014	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—uterine cancer	0.0005	0.00139	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000496	0.00138	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000487	0.00136	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—uterine cancer	0.000485	0.00135	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—uterine cancer	0.000482	0.00135	CcSEcCtD
Pimecrolimus—Nausea—Dactinomycin—uterine cancer	0.00048	0.00134	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—uterine cancer	0.000479	0.00134	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—uterine cancer	0.000478	0.00133	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—uterine cancer	0.000476	0.00133	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—uterine cancer	0.000476	0.00133	CcSEcCtD
Pimecrolimus—Urticaria—Etoposide—uterine cancer	0.000465	0.0013	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—uterine cancer	0.000463	0.00129	CcSEcCtD
Pimecrolimus—Body temperature increased—Etoposide—uterine cancer	0.000463	0.00129	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—uterine cancer	0.000463	0.00129	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—uterine cancer	0.000463	0.00129	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—uterine cancer	0.000458	0.00128	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—uterine cancer	0.000449	0.00125	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—uterine cancer	0.000446	0.00125	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—uterine cancer	0.000431	0.0012	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etoposide—uterine cancer	0.000431	0.0012	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—uterine cancer	0.000428	0.0012	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—uterine cancer	0.000428	0.00119	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—uterine cancer	0.000424	0.00118	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—uterine cancer	0.000417	0.00116	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—uterine cancer	0.000416	0.00116	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—uterine cancer	0.000414	0.00115	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—uterine cancer	0.000402	0.00112	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—uterine cancer	0.000402	0.00112	CcSEcCtD
Pimecrolimus—Diarrhoea—Etoposide—uterine cancer	0.0004	0.00112	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—uterine cancer	0.000399	0.00111	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—uterine cancer	0.000396	0.00111	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—uterine cancer	0.000389	0.00108	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—uterine cancer	0.000386	0.00108	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—uterine cancer	0.000385	0.00107	CcSEcCtD
Pimecrolimus—Vomiting—Etoposide—uterine cancer	0.000372	0.00104	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—uterine cancer	0.000372	0.00104	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—uterine cancer	0.000372	0.00104	CcSEcCtD
Pimecrolimus—Rash—Etoposide—uterine cancer	0.000369	0.00103	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—uterine cancer	0.000369	0.00103	CcSEcCtD
Pimecrolimus—Headache—Etoposide—uterine cancer	0.000367	0.00102	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—uterine cancer	0.00036	0.001	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—uterine cancer	0.000351	0.000978	CcSEcCtD
Pimecrolimus—Nausea—Etoposide—uterine cancer	0.000348	0.00097	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—uterine cancer	0.000342	0.000955	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00034	0.000948	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—uterine cancer	0.000328	0.000915	CcSEcCtD
Pimecrolimus—Oedema—Epirubicin—uterine cancer	0.000328	0.000915	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—uterine cancer	0.000326	0.000909	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—uterine cancer	0.000325	0.000905	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—uterine cancer	0.000322	0.000897	CcSEcCtD
Pimecrolimus—Skin disorder—Epirubicin—uterine cancer	0.000319	0.000889	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—uterine cancer	0.000317	0.000883	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000314	0.000877	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—uterine cancer	0.000303	0.000847	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—uterine cancer	0.000303	0.000847	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—uterine cancer	0.000302	0.000841	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000299	0.000834	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—uterine cancer	0.000298	0.00083	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—uterine cancer	0.000295	0.000822	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—uterine cancer	0.000295	0.000822	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—uterine cancer	0.000292	0.000816	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000283	0.00079	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—uterine cancer	0.00028	0.000782	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—uterine cancer	0.00028	0.000782	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000277	0.000771	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—uterine cancer	0.000273	0.00076	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—uterine cancer	0.000271	0.000755	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Epirubicin—uterine cancer	0.000268	0.000748	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000262	0.000731	CcSEcCtD
Pimecrolimus—Urticaria—Epirubicin—uterine cancer	0.000261	0.000727	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—uterine cancer	0.00026	0.000724	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—uterine cancer	0.00026	0.000724	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—uterine cancer	0.000259	0.000723	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—uterine cancer	0.000259	0.000723	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000248	0.000692	CcSEcCtD
Pimecrolimus—Hypersensitivity—Epirubicin—uterine cancer	0.000242	0.000674	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—uterine cancer	0.000241	0.000673	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—uterine cancer	0.00024	0.000669	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—uterine cancer	0.00024	0.000669	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—uterine cancer	0.000236	0.000764	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—AKT1—uterine cancer	0.000233	0.000754	CbGpPWpGaD
Pimecrolimus—Pruritus—Epirubicin—uterine cancer	0.000232	0.000647	CcSEcCtD
Pimecrolimus—MTOR—GAB1 signalosome—AKT1—uterine cancer	0.000231	0.000748	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—NRAS—uterine cancer	0.00023	0.000745	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—NRAS—uterine cancer	0.00023	0.000745	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—uterine cancer	0.00023	0.000745	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—uterine cancer	0.00023	0.000744	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—uterine cancer	0.000228	0.00074	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—NRAS—uterine cancer	0.000228	0.000738	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	0.000227	0.000737	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—uterine cancer	0.000227	0.000736	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—uterine cancer	0.000226	0.000732	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—AKT1—uterine cancer	0.000226	0.000731	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—uterine cancer	0.000226	0.000731	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—NRAS—uterine cancer	0.000225	0.000729	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	0.000225	0.000728	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Epirubicin—uterine cancer	0.000224	0.000626	CcSEcCtD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.000224	0.000727	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Doxorubicin—uterine cancer	0.000224	0.000624	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—KRAS—uterine cancer	0.000224	0.000724	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—uterine cancer	0.000222	0.00072	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKR1B10—uterine cancer	0.00022	0.000714	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—PIK3CA—uterine cancer	0.000218	0.000707	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SOCS3—uterine cancer	0.000215	0.000698	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKR1C1—uterine cancer	0.000215	0.000696	CbGpPWpGaD
Pimecrolimus—Pruritus—Doxorubicin—uterine cancer	0.000215	0.000599	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—KRAS—uterine cancer	0.000214	0.000692	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—NRAS—uterine cancer	0.000213	0.000689	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—uterine cancer	0.000212	0.000688	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KRAS—uterine cancer	0.000212	0.000688	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.000212	0.000686	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—KRAS—uterine cancer	0.000211	0.000685	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KRAS—uterine cancer	0.00021	0.000682	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—AKT1—uterine cancer	0.00021	0.000679	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—uterine cancer	0.000209	0.000676	CbGpPWpGaD
Pimecrolimus—Vomiting—Epirubicin—uterine cancer	0.000209	0.000582	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—CXCL8—uterine cancer	0.000208	0.000674	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Doxorubicin—uterine cancer	0.000208	0.000579	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—uterine cancer	0.000207	0.000672	CbGpPWpGaD
Pimecrolimus—Rash—Epirubicin—uterine cancer	0.000207	0.000577	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—uterine cancer	0.000207	0.000576	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—ERBB2—uterine cancer	0.000206	0.000667	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKR1C3—uterine cancer	0.000206	0.000667	CbGpPWpGaD
Pimecrolimus—Headache—Epirubicin—uterine cancer	0.000205	0.000573	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—PIK3CA—uterine cancer	0.000205	0.000665	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN2B—uterine cancer	0.000205	0.000665	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—uterine cancer	0.000204	0.00066	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN1B—uterine cancer	0.000203	0.000659	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—uterine cancer	0.000202	0.000654	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PGR—uterine cancer	0.000201	0.00065	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—uterine cancer	0.0002	0.000647	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—uterine cancer	0.000198	0.000643	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KRAS—uterine cancer	0.000198	0.000641	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—uterine cancer	0.000198	0.000641	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KRAS—uterine cancer	0.000198	0.000641	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—PIK3CA—uterine cancer	0.000197	0.000639	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—PIK3CA—uterine cancer	0.000196	0.000635	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—KRAS—uterine cancer	0.000196	0.000635	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—PIK3CA—uterine cancer	0.000195	0.000632	CbGpPWpGaD
Pimecrolimus—Nausea—Epirubicin—uterine cancer	0.000195	0.000544	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—uterine cancer	0.000194	0.00063	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—PIK3CA—uterine cancer	0.000194	0.000629	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KRAS—uterine cancer	0.000194	0.000627	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—PIK3CA—uterine cancer	0.000193	0.000626	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—uterine cancer	0.000193	0.000626	CbGpPWpGaD
Pimecrolimus—Vomiting—Doxorubicin—uterine cancer	0.000193	0.000538	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—YWHAE—uterine cancer	0.000191	0.00062	CbGpPWpGaD
Pimecrolimus—Rash—Doxorubicin—uterine cancer	0.000191	0.000534	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—uterine cancer	0.000191	0.000533	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—CDKN1B—uterine cancer	0.000191	0.000618	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—uterine cancer	0.000191	0.000617	CbGpPWpGaD
Pimecrolimus—Headache—Doxorubicin—uterine cancer	0.00019	0.00053	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—uterine cancer	0.00019	0.000616	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SMAD3—uterine cancer	0.000188	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGFR2—uterine cancer	0.000187	0.000606	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—DCN—uterine cancer	0.000186	0.000602	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FBXW7—uterine cancer	0.000184	0.000595	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KRAS—uterine cancer	0.000183	0.000593	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RNF43—uterine cancer	0.000183	0.000592	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—uterine cancer	0.000182	0.000591	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PIK3CA—uterine cancer	0.000182	0.000589	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PIK3CA—uterine cancer	0.000182	0.000589	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—uterine cancer	0.000182	0.000589	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—uterine cancer	0.000182	0.000588	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—uterine cancer	0.000181	0.000585	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—uterine cancer	0.000181	0.000585	CbGpPWpGaD
Pimecrolimus—Nausea—Doxorubicin—uterine cancer	0.00018	0.000503	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—PIK3CA—uterine cancer	0.00018	0.000584	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—uterine cancer	0.00018	0.000582	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGFR2—uterine cancer	0.00018	0.000582	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—uterine cancer	0.000179	0.000579	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGFR2—uterine cancer	0.000179	0.000579	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—uterine cancer	0.000179	0.000579	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—EP300—uterine cancer	0.000179	0.000578	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—AKT1—uterine cancer	0.000178	0.000577	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRF1—uterine cancer	0.000178	0.000577	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PIK3CA—uterine cancer	0.000178	0.000576	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—uterine cancer	0.000176	0.000571	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PTEN—uterine cancer	0.000176	0.000569	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—uterine cancer	0.000175	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—uterine cancer	0.000175	0.000568	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—uterine cancer	0.000172	0.000558	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—uterine cancer	0.000171	0.000552	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—uterine cancer	0.000169	0.000548	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	0.000169	0.000546	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PIK3CA—uterine cancer	0.000168	0.000545	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—uterine cancer	0.000168	0.000545	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—uterine cancer	0.000168	0.000545	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—uterine cancer	0.000168	0.000545	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—uterine cancer	0.000168	0.000544	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	0.000167	0.000542	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INHBA—uterine cancer	0.000167	0.000541	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—uterine cancer	0.000167	0.00054	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKR1C3—uterine cancer	0.000165	0.000536	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—uterine cancer	0.000165	0.000535	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	0.000165	0.000535	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—uterine cancer	0.000165	0.000533	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HMGA1—uterine cancer	0.000161	0.000522	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—uterine cancer	0.000161	0.000522	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—uterine cancer	0.000161	0.000522	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STK11—uterine cancer	0.00016	0.00052	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—uterine cancer	0.00016	0.000519	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FBXW7—uterine cancer	0.00016	0.000517	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—uterine cancer	0.000159	0.000517	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—uterine cancer	0.000159	0.000517	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—uterine cancer	0.000159	0.000514	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—uterine cancer	0.000158	0.000512	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—uterine cancer	0.000157	0.000507	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—uterine cancer	0.000156	0.000504	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—uterine cancer	0.000156	0.000504	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKR1C1—uterine cancer	0.00015	0.000487	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SOCS3—uterine cancer	0.00015	0.000487	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	0.000149	0.000483	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	0.000149	0.000481	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—uterine cancer	0.000149	0.000481	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—uterine cancer	0.000149	0.000481	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FBXW7—uterine cancer	0.000147	0.000477	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—uterine cancer	0.000147	0.000477	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—uterine cancer	0.000146	0.000473	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—uterine cancer	0.000145	0.000471	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN2B—uterine cancer	0.000144	0.000466	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1R—uterine cancer	0.00014	0.000452	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—uterine cancer	0.000137	0.000445	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—uterine cancer	0.000135	0.000437	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDH1—uterine cancer	0.000134	0.000433	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	0.000132	0.000426	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMAD3—uterine cancer	0.000131	0.000425	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SOCS3—uterine cancer	0.000131	0.000423	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—uterine cancer	0.000128	0.000414	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR2—uterine cancer	0.000125	0.000406	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PIK3CA—uterine cancer	0.000124	0.000401	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—uterine cancer	0.000117	0.00038	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKR1C3—uterine cancer	0.000116	0.000375	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN2B—uterine cancer	0.000115	0.000374	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—uterine cancer	0.000115	0.000371	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PGR—uterine cancer	0.000113	0.000366	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—uterine cancer	0.000113	0.000365	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—uterine cancer	0.000112	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR2—uterine cancer	0.000109	0.000353	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1B—uterine cancer	0.000109	0.000352	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—YWHAE—uterine cancer	0.000108	0.000349	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ESR1—uterine cancer	0.000107	0.000347	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SMAD3—uterine cancer	0.000105	0.000342	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1B—uterine cancer	0.000104	0.000338	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1B—uterine cancer	0.000104	0.000337	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FBXW7—uterine cancer	0.000103	0.000334	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTNNB1—uterine cancer	0.000103	0.000333	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—uterine cancer	0.000101	0.000328	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR2—uterine cancer	0.000101	0.000326	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—uterine cancer	0.0001	0.000324	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CTNNB1—uterine cancer	9.83e-05	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—uterine cancer	9.68e-05	0.000314	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—uterine cancer	9.62e-05	0.000312	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—uterine cancer	9.58e-05	0.00031	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EP300—uterine cancer	9.55e-05	0.000309	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—uterine cancer	9.43e-05	0.000306	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EP300—uterine cancer	9.13e-05	0.000296	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STK11—uterine cancer	9.02e-05	0.000292	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SRD5A2—uterine cancer	8.99e-05	0.000291	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NDUFB11—uterine cancer	8.99e-05	0.000291	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—uterine cancer	8.94e-05	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—uterine cancer	8.58e-05	0.000278	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—uterine cancer	8.54e-05	0.000277	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS3—uterine cancer	8.45e-05	0.000274	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—uterine cancer	8.11e-05	0.000263	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN2B—uterine cancer	8.09e-05	0.000262	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—uterine cancer	7.86e-05	0.000255	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1R—uterine cancer	7.85e-05	0.000254	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—uterine cancer	7.69e-05	0.000249	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—uterine cancer	7.46e-05	0.000242	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—uterine cancer	7.39e-05	0.000239	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMAD3—uterine cancer	7.38e-05	0.000239	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—uterine cancer	7.35e-05	0.000238	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1B—uterine cancer	7.28e-05	0.000236	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—uterine cancer	7.07e-05	0.000229	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR2—uterine cancer	7.04e-05	0.000228	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—uterine cancer	6.88e-05	0.000223	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—uterine cancer	6.84e-05	0.000222	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—uterine cancer	6.79e-05	0.00022	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—uterine cancer	6.76e-05	0.000219	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—uterine cancer	6.71e-05	0.000217	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—uterine cancer	6.54e-05	0.000212	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1B1—uterine cancer	6.5e-05	0.000211	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STAR—uterine cancer	6.5e-05	0.000211	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EP300—uterine cancer	6.4e-05	0.000207	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1B—uterine cancer	6.34e-05	0.000205	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—uterine cancer	6.32e-05	0.000205	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—uterine cancer	6.28e-05	0.000203	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—uterine cancer	6.25e-05	0.000202	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—uterine cancer	6.06e-05	0.000196	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—uterine cancer	6.03e-05	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—uterine cancer	5.99e-05	0.000194	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—uterine cancer	5.98e-05	0.000194	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1B—uterine cancer	5.85e-05	0.000189	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—uterine cancer	5.83e-05	0.000189	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—uterine cancer	5.77e-05	0.000187	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EP300—uterine cancer	5.56e-05	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—uterine cancer	5.54e-05	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—uterine cancer	5.53e-05	0.000179	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—uterine cancer	5.52e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—uterine cancer	5.39e-05	0.000174	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—uterine cancer	5.31e-05	0.000172	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—uterine cancer	5.2e-05	0.000169	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—uterine cancer	5.15e-05	0.000167	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EP300—uterine cancer	5.14e-05	0.000166	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—POLD1—uterine cancer	5.1e-05	0.000165	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—uterine cancer	4.81e-05	0.000156	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C1—uterine cancer	4.77e-05	0.000155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—uterine cancer	4.73e-05	0.000153	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—uterine cancer	4.58e-05	0.000148	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—uterine cancer	4.48e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—uterine cancer	4.42e-05	0.000143	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—uterine cancer	4.38e-05	0.000142	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RRM2—uterine cancer	4.25e-05	0.000138	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—uterine cancer	4.19e-05	0.000136	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—uterine cancer	4.14e-05	0.000134	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DCN—uterine cancer	4.13e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—uterine cancer	4.12e-05	0.000133	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1B—uterine cancer	4.1e-05	0.000133	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP11A1—uterine cancer	3.89e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—uterine cancer	3.87e-05	0.000125	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—uterine cancer	3.86e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—uterine cancer	3.81e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—uterine cancer	3.8e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—uterine cancer	3.77e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C3—uterine cancer	3.67e-05	0.000119	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EP300—uterine cancer	3.6e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—uterine cancer	3.52e-05	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—uterine cancer	3.41e-05	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—uterine cancer	3.36e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—uterine cancer	3.36e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—uterine cancer	3.1e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—uterine cancer	2.9e-05	9.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STK11—uterine cancer	2.86e-05	9.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.86e-05	9.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—uterine cancer	2.66e-05	8.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—uterine cancer	2.57e-05	8.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—uterine cancer	2.46e-05	7.97e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—uterine cancer	2.17e-05	7.04e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—uterine cancer	2.15e-05	6.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—uterine cancer	1.2e-05	3.88e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EP300—uterine cancer	1.14e-05	3.7e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—uterine cancer	8.44e-06	2.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—uterine cancer	6.9e-06	2.23e-05	CbGpPWpGaD
